Keyword: Bristol-Myers Squibb
BMS’ tyrosine kinase 2 inhibitor checked off a phase 2 psoriasis trial, showing high levels of skin clearance after three months of daily treatment.
An Allergan architect bids farewell as its board revamp continues; Gilead steals the commercial chief from Amgen; Editas loses its CMO and more.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China.
Nowers joins from Gilead’s Kite at a time when Cell Medica is seeking to push CAR and TCR candidates through development and on to the market.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
Gilead's top executives step down, Amgen's R&D head leaves for the startup scene, and BMS' commercial chief jumps ship.
The data link Merck’s doravirine to a higher rate of viral suppression than a combination of antiretroviral drugs from AbbVie and Johnson & Johnson.
The agreement tasks Tsinghua with discovering cancer and autoimmune disease therapeutics that Bristol-Myers can then choose to license.
Human Longevity CFO/COO departs after scandal; Sangamo loses another top executive; McCann Health fires chief creative for conduct violation and more.